首页> 外文期刊>Reproductive biomedicine online >Symposium: Update on prediction and management of OHSS. Prevention of OHSS--dopamine agonists.
【24h】

Symposium: Update on prediction and management of OHSS. Prevention of OHSS--dopamine agonists.

机译:专题讨论会:OHSS的预测和管理的最新进展。预防OHSS-多巴胺激动剂。

获取原文
获取原文并翻译 | 示例

摘要

Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic complication of ovulation induction, which may seriously affect the patient's health, with 0.1-2.0% of the patients developing severe forms of the syndrome. OHSS signs and symptoms are direct consequences of fluid shift from capillaries to the third space due to increased vascular permeability. The mechanisms of OHSS pathophysiology remain unknown but evidence obtained in animal models prove that vascular endothelial growth factor (VEGF) is directly involved and the inhibition of the VEGF system could prevent OHSS from occurring. Dopamine agonists impede the phosphorylation of the VEGF receptor 2 and reduce the incidence and severity of OHSS with a safe clinical profile. As far as is known, this is the first pathophysiological approach for treatment and prevention of OHSS.
机译:卵巢过度刺激综合症(OHSS)是引起排卵的医源性并发症,可能严重影响患者的健康,其中0.1-2.0%的患者发展为严重形式的综合征。 OHSS的体征和症状是由于血管通透性增加导致液体从毛细血管转移到第三腔的直接结果。 OHSS病理生理学的机制仍然未知,但是在动物模型中获得的证据证明,血管内皮生长因子(VEGF)直接参与其中,而VEGF系统的抑制作用可以阻止OHSS的发生。多巴胺激动剂可通过安全的临床表现阻止VEGF受体2的磷酸化并降低OHSS的发生率和严重性。众所周知,这是治疗和预防OHSS的第一种病理生理学方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号